BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 2166430)

  • 1. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy.
    Yamada T; Takasu N; Sato A; Aizawa T; Koizumi Y
    J Clin Endocrinol Metab; 1982 Jan; 54(1):83-8. PubMed ID: 6798061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
    Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
    Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
    Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
    Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.